ATE263565T1 - Verwendung von 8,9-dehydroestron zur herstellung eines arzneimittels zur behandlung von durch freie radikale verursachte krankheiten - Google Patents

Verwendung von 8,9-dehydroestron zur herstellung eines arzneimittels zur behandlung von durch freie radikale verursachte krankheiten

Info

Publication number
ATE263565T1
ATE263565T1 AT96308632T AT96308632T ATE263565T1 AT E263565 T1 ATE263565 T1 AT E263565T1 AT 96308632 T AT96308632 T AT 96308632T AT 96308632 T AT96308632 T AT 96308632T AT E263565 T1 ATE263565 T1 AT E263565T1
Authority
AT
Austria
Prior art keywords
dehydroestrone
treatment
production
free radicals
diseases caused
Prior art date
Application number
AT96308632T
Other languages
English (en)
Inventor
Steven Jay Adelman
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of ATE263565T1 publication Critical patent/ATE263565T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
AT96308632T 1995-12-04 1996-11-28 Verwendung von 8,9-dehydroestron zur herstellung eines arzneimittels zur behandlung von durch freie radikale verursachte krankheiten ATE263565T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US793195P 1995-12-04 1995-12-04

Publications (1)

Publication Number Publication Date
ATE263565T1 true ATE263565T1 (de) 2004-04-15

Family

ID=21728885

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96308632T ATE263565T1 (de) 1995-12-04 1996-11-28 Verwendung von 8,9-dehydroestron zur herstellung eines arzneimittels zur behandlung von durch freie radikale verursachte krankheiten

Country Status (23)

Country Link
EP (1) EP0778025B1 (de)
JP (1) JPH09169650A (de)
KR (1) KR100444002B1 (de)
CN (1) CN1104900C (de)
AR (2) AR005866A1 (de)
AT (1) ATE263565T1 (de)
AU (1) AU703814B2 (de)
BR (1) BR9605777A (de)
CA (1) CA2191835A1 (de)
CZ (1) CZ289780B6 (de)
DE (1) DE69632117T2 (de)
DK (1) DK0778025T3 (de)
ES (1) ES2215187T3 (de)
HK (1) HK1010095A1 (de)
HU (1) HUP9603329A3 (de)
IL (1) IL119744A (de)
MX (1) MX9606009A (de)
NO (1) NO312654B1 (de)
NZ (1) NZ299858A (de)
PT (1) PT778025E (de)
SI (1) SI0778025T1 (de)
SK (1) SK154296A3 (de)
ZA (1) ZA969923B (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19723794A1 (de) * 1997-06-06 1998-12-10 Jenapharm Gmbh Nichtestrogene Derivate des Estradiols mit antioxidativer Aktivität
US9557325B2 (en) 2003-06-09 2017-01-31 Redox-Reactive Reagents Llc Method of altering the binding specificity of proteins by oxidation-reduction reactions
US7892751B2 (en) 2003-06-09 2011-02-22 Redox-Reactive Reagents Llc Method of detecting or diagnosing of a neurodegenerative disease or condition
ATE518886T1 (de) 2003-06-09 2011-08-15 Redox Reactive Reagents L L C Verfahren zur änderung der bindungsspezifität von plasmaproteinen durch oxidations- reduktionsreaktionen

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5210081A (en) * 1992-02-26 1993-05-11 American Home Products Corporation Alkali metal 8,9-dehydroestrone sulfate esters
DE4334823C2 (de) * 1993-10-09 1998-09-17 Schering Ag Verfahren zur Herstellung von Schwefelsäurehalbestern von Estrogenen
US5395831A (en) * 1994-04-08 1995-03-07 American Home Products Corporation Treating cardiac disorders with Δ9(11)-dehydro-8-isoestrone
DE19509729A1 (de) * 1995-03-13 1996-09-19 Schering Ag 17-Difluormethylen-Estratriene

Also Published As

Publication number Publication date
AR059965A2 (es) 2008-05-14
PT778025E (pt) 2004-08-31
CZ289780B6 (cs) 2002-04-17
DE69632117T2 (de) 2004-08-26
CA2191835A1 (en) 1997-06-05
EP0778025A1 (de) 1997-06-11
DE69632117D1 (de) 2004-05-13
IL119744A0 (en) 1997-03-18
KR100444002B1 (ko) 2004-11-03
IL119744A (en) 2003-01-12
HK1010095A1 (en) 1999-06-11
CZ353296A3 (en) 1997-08-13
NZ299858A (en) 2001-03-30
BR9605777A (pt) 1998-08-25
HU9603329D0 (en) 1997-01-28
NO965165L (no) 1997-06-05
HUP9603329A2 (en) 1997-08-28
ZA969923B (en) 1998-05-26
AU703814B2 (en) 1999-04-01
SI0778025T1 (en) 2004-08-31
ES2215187T3 (es) 2004-10-01
DK0778025T3 (da) 2004-06-07
EP0778025B1 (de) 2004-04-07
AU7194496A (en) 1997-06-12
MX9606009A (es) 1997-08-30
CN1158725A (zh) 1997-09-10
KR970032870A (ko) 1997-07-22
AR005866A1 (es) 1999-07-21
CN1104900C (zh) 2003-04-09
NO965165D0 (no) 1996-12-03
SK154296A3 (en) 1997-08-06
HUP9603329A3 (en) 1998-01-28
NO312654B1 (no) 2002-06-17
JPH09169650A (ja) 1997-06-30

Similar Documents

Publication Publication Date Title
DE3484055D1 (de) Verwendung von ubidecarenon zur herstellung eines medikaments zur behandlung von durch radiotherapie hervorgerufenen geschwueren.
DE69629184D1 (de) Verwendung von vitamin d2 oder vitamin d4-derivaten zur herstellung eines medikamentes zur behandlung des sekundären hyperparathyroidismus
ATE234095T1 (de) Produkt enthaltend rapamycin oder ausgewählte derivate und einen nmda- oder ampa-antagonisten zur verwendung für die behandlung von epilepsie oder morbus huntington, und die verwendung von rapamycin oder von ausgewählten derivaten für die herstellung eines medikaments für die behandlung von epilepsie oder morbus huntington.
DE69426320D1 (de) Verwendung von silikon/fluorsilikon kopolymeröl zur herstellung eines arzneimittels zur behandlung von augenerkrankungen
DE69824576D1 (de) Verwendung von tetrahydropyridinderivaten zur herstellung von arzneimitteln zur behandlung demyelinisierender erkrankungen
ATE335487T1 (de) Verwendung von pyridazino 4,5-(b)ö-indole-1- acetamide derivaten zur herstellung eines arzneimittels zur behandlung von durch periphere benzodiazepinrezeptoren-störungen verursachte krankheiten
ATE191849T1 (de) Verwendung von (s)-(-)-alpha-ethyl-2-oxo-1- pyrrolidinacetamid zur herstellung eines medikaments zur behandlung von angst
ATE246518T1 (de) Egr-1 zur herstellung eines medikamentes zur behandlung von wunden
DE69635298D1 (de) Verwendung von Acetylsalicylsäuren zur Herstellung eines Medikaments für die Behandlung von Hautverletzungen
DE69613597T2 (de) Verfahren zur Herstellung von Cyclopentadienyl-Verbindungen und nach dem Verfahren hergestellte Verbindungen
DE69423577D1 (de) Verwendung von Oenothein B zur Herstellung eines Medikaments zur Behandlung der durch Hyperandrogenität bedingte Störungen.
DE69232911D1 (de) Verwendung eines polyhydroxybenzamids oder dessen Derivat zur Herstellung eines Medikaments für die Behandlung von viralen Infektionen
ATE263565T1 (de) Verwendung von 8,9-dehydroestron zur herstellung eines arzneimittels zur behandlung von durch freie radikale verursachte krankheiten
DE3768150D1 (de) Verwendung eines 1,3-oxazolidin-2-on-derivates zur herstellung eines arzneimittels zur behandlung von ischaemie.
DE69632677D1 (de) Verwendung eines Rifamycin-Derivates zur Herstellung eines Medikamentes zur Behandlung von Krankheiten verursacht durch Helicobacter pylori-Infektionen
DE69003960T2 (de) Die Verwendung von deacetyliertem Chitin zur Herstellung eines Medikamentes für die Behandlung von entzündliche Krankheiten.
DE69620786T2 (de) Verwendung von cholinesterase-inhibitoren für die herstellung eines medikaments zur behandlung von xerostomie
DE68905657D1 (de) Verwendung von arginin-aspartat zur herstellung eines arzneimittels zur behandlung gewisser gedaechtnisstoerungen.
DE69515666T2 (de) VERWENDUNG VON GnRH-ANTAGONISTEN ZUR HERSTELLUNG EINES MEDIKAMENTS ZUR BEHANDLUNG GONADEN-STEROID ABHÄNGIGER ERKRANKUNGEN
DE59607664D1 (de) Verfahren zur Herstellung von 2,4,4,7-Tetramethyl-oct-6-en-3-on und dessen Verwendung als Riechstoff
DE69610045D1 (de) Verwendung eines Rohpflanzenextraktes zur Herstellung eines Arzneimittels zur Behandlung von HIV-Infektionen
ATE192650T1 (de) Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung parkinsonscher krankheit
DE3578374D1 (de) Verwendung von chinolonen fuer die herstellung eines arzneimittels zur behandlung von herzerkrankungen.
DE3483944D1 (de) Verwendung von selektiv peripheren dopamin-antagonisten zur herstellung eines arzneimittels zur topischen behandlung von okularer hypertension.
ATE186640T1 (de) Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung neurogenerativer erkrankungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0778025

Country of ref document: EP

REN Ceased due to non-payment of the annual fee